This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co has settled its patent litigation against generic drug firm Glenmark Pharmaceuticals over Merck’s cholesterol lowering
drug Zetia (ezetimibe). The case was set to go to trial on 12 May, after Glenmark sought US Food and Drug Administration approval
to market a generic version of ezetimibe, which is still under patent protection until April 2017. Under terms of the settlement,
Glenmark will be able to sell ezetimibe from December 2016.
The rest of this document is only available to i-law.com online
If you are already a subscriber, please enter your details below to log in.